| Schedule of Disaggregation of Revenue |
The following table presents revenue from contracts with customers by product category and platform for the three and six-month periods ended June 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Foundational | | | | | | | | | | | | | Access | | $ | 161,786 | | $ | 152,122 | | $ | 312,910 | | $ | 286,520 | OEM | | | 48,338 | | | 43,218 | | | 87,878 | | | 86,641 | Procedural Solutions | | | 27,949 | | | 31,741 | | | 54,437 | | | 60,310 | Vascular Intervention | | | 41,652 | | | 34,955 | | | 80,690 | | | 67,804 | Other | | | 1,236 | | | 346 | | | 525 | | | 1,489 | Total Foundational | | | 280,961 | | | 262,382 | | | 536,440 | | | 502,764 | | | | | | | | | | | | | | Therapeutic | | | | | | | | | | | | | Cardiac Therapies | | | 28,510 | | | 22,930 | | | 55,914 | | | 43,489 | Endoscopy | | | 23,647 | | | 18,400 | | | 45,339 | | | 34,951 | OEM | | | 12,797 | | | 9,735 | | | 20,276 | | | 20,877 | Oncology | | | 25,774 | | | 23,943 | | | 49,282 | | | 45,994 | Renal Therapies | | | 12,713 | | | 12,817 | | | 24,225 | | | 26,206 | Vascular Intervention | | | 34,441 | | | 32,255 | | | 69,244 | | | 63,532 | Total Therapeutic | | | 137,882 | | | 120,080 | | | 264,280 | | | 235,049 | | | | | | | | | | | | | | Total | | $ | 418,843 | | $ | 382,462 | | $ | 800,720 | | $ | 737,813 |
The following table presents revenue from contracts with customers by geographic region for the the three and six-month periods ended June 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Domestic | | $ | 252,051 | | $ | 227,082 | | $ | 478,567 | | $ | 440,646 | International | | | 166,792 | | | 155,380 | | | 322,153 | | | 297,167 | Total | | $ | 418,843 | | $ | 382,462 | | $ | 800,720 | | $ | 737,813 |
|